Grissinger Michael 4

What Happened

• Michael Grissinger, a director of Adicet Bio, was granted 4,200 shares on June 21, 2026. The grant was reported as an award/derivative transaction with an acquisition price of $0.00 (reported value $0). This is a compensation award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-21; Form 4 filed: 2026-06-23 (filed within the typical 2-business-day reporting window).
• Transaction type: Award/Grant (derivative) — 4,200 shares acquired at $0.00.
• Reported value: $0 (no cash exchanged at grant).
• Shares owned following the transaction: Not disclosed in the provided filing.
• Footnote: These shares vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to the reporting person’s continued board service.

Context

• Director equity awards are common as compensation and retention tools; they do not necessarily signal immediate bullish or bearish trading intent. This grant vests based on continued service and is not an exercised option or a sale.